In summary, our results, as shown in Figure 7, demonstrate that BTK-mTOR inhibition disrupts the population of GBM CSCs and contributes to normalizing GBM vascularization, which in turn facilitates the delivery of anticancer drugs and reduces the hypoxia of tumor cells. This evidence concerns the gene MTOR and glioblastoma.